During the past decade, Instituto Clinico Oncologico del Sur ICOS conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 15 clinical trials were completed, i.e. on average, 187.5% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 7 clinical trials were completed. i.e. 700% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto Clinico Oncologico del Sur ICOS" #1 sponsor was "Pfizer" with 7 trials, followed by "Boehringer Ingelheim" with 3 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 2 trials sponsored, "Alaunos Therapeutics" with 1 trials sponsored and "Celgene" with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto Clinico Oncologico del Sur ICOS" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 3 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "Eisai Europe Ltd. (United Kingdom)" with 1 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 1 trials as a collaborator and "Ono Pharmaceutical Co. Ltd" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Instituto Clinico Oncologico del Sur ICOS" are "Carcinoma, Non-Small-Cell Lung" (3 trials), "Chronic Myeloid Leukemia" (2 trials), "Non-Small Cell Lung Cancer" (2 trials), "Adenocarcinoma" (1 trials) and "B-Cell Chronic Lymphocytic Leukemia" (1 trials). Many other conditions were trialed in "Instituto Clinico Oncologico del Sur ICOS" in a lesser frequency.

Most popular intervention types in "Instituto Clinico Oncologico del Sur ICOS" are "Drug" (20 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Carboplatin" (3 trials), "Paclitaxel" (3 trials), "5-Fluorouracil" (2 trials) and "BIBW 2992" (2 trials). Other intervention names were less common.

The vast majority of trials in "Instituto Clinico Oncologico del Sur ICOS" are 17 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Instituto Clinico Oncologico del Sur ICOS". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Instituto Clinico Oncologico del Sur ICOS, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto Clinico Oncologico del Sur ICOS, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".